 | Up a level |
Aminkeng, Folefac; Ross, Colin J D; Rassekh, Shahrad R; Rieder, Michael J; Bhavsar, Amit P; Sanatani, Shubhayan; Bernstein, Daniel; Hayden, Michael R; Amstutz, Ursula; Carleton, Bruce C (2017). Pharmacogenomic screening for anthracycline-induced cardiotoxicity in childhood cancer. British journal of clinical pharmacology, 83(5), pp. 1143-1145. Wiley-Blackwell 10.1111/bcp.13218
Aminkeng, Folefac; Ross, Colin J D; Rassekh, Shahrad R; Hwang, Soomi; Rieder, Michael J; Bhavsar, Amit P; Smith, Anne; Sanatani, Shubhayan; Gelmon, Karen A; Bernstein, Daniel; Hayden, Michael R; Carleton, Bruce C; Amstutz, Ursula (2016). Recommendations for Genetic Testing to Reduce the Incidence of Anthracycline-induced Cardiotoxicity. British journal of clinical pharmacology, 82(3), pp. 683-695. Wiley-Blackwell 10.1111/bcp.13008
Aminkeng, Folefac; Bhavsar, Amit P; Visscher, Henk; Rassekh, Shahrad R; Li, Yuling; Lee, Jong W; Brunham, Liam R; Caron, Huib N; van Dalen, Elvira C; Kremer, Leontien C; van der Pal, Helena J; Amstutz, Ursula; Rieder, Michael J; Bernstein, Daniel; Carleton, Bruce C; Hayden, Michael R; Ross, Colin J D (2015). A coding variant in RARG confers susceptibility to anthracycline-induced cardiotoxicity in childhood cancer. Nature genetics, 47(9), pp. 1079-1084. Nature America 10.1038/ng.3374
Visscher, Henk; Rassekh, S Rod; Sandor, George S; Caron, Huib N; van Dalen, Elvira C; Kremer, Leontien C; van der Pal, Helena J; Rogers, Paul C; Rieder, Michael J; Carleton, Bruce C; Hayden, Michael R; Ross, Colin J; Amstutz, Ursula; Canadian Pharmacogenomics Network for Drug Safety consortium, CPNDS (2015). Genetic variants in SLC22A17 and SLC22A7 are associated with anthracycline-induced cardiotoxicity in children. Pharmacogenomics, 16(10), pp. 1065-1076. Future Medicine 10.2217/pgs.15.61
Amstutz, Ursula; Shear, Neil H; Rieder, Michael J; Hwang, Soomi; Fung, Vincent; Nakamura, Hidefumi; Connolly, Mary B; Ito, Shinya; Carleton, Bruce C (2014). Recommendations for HLA-B*15:02 and HLA-A*31:01 genetic testing to reduce the risk of carbamazepine-induced hypersensitivity reactions. Epilepsia, 55(4), pp. 496-506. Wiley-Blackwell 10.1111/epi.12564
